Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SCB 2020S

X
Drug Profile

SCB 2020S

Alternative Names: B.1.351 S-Trimer vaccine - Clover Biopharmaceuticals; Endemic coronavirus vaccine - Clover Biopharmaceuticals; Multiple variants SARS-CoV-2 vaccine - Clover Biopharmaceuticals; Multivalent SARS-COV2 vaccine - Clover Biopharmaceuticals; SARS-CoV-2 S-Trimer B.1.351 variant vaccine - Clover Biopharmaceuticals; SCB-2020-S

Latest Information Update: 13 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Clover Biopharmaceuticals
  • Class COVID-19 vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I COVID 2019 infections

Most Recent Events

  • 23 Apr 2023 Clover Biopharmaceuticals completes phase I trial in COVID-2019 infections (Prevention) in South Africa (IM) (NCT05228314)
  • 31 May 2022 Phase-I clinical trials in COVID-2019 infections (Prevention) in South Africa (IM) (NCT05228314)
  • 05 May 2022 Clover Biopharmaceuticals plans a phase I trial for COVID-2019-infections (Prevention) in 2Q of 2022 (IM) (NCT05228314)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top